Conor E Steuer

Trials

Studies that name Conor E Steuer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:42 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT06495125 · Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

  Emory University · recruiting · Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8 · principal investigator
• Ph2
  NCT04262869 · Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer

  Emory University · withdrawn · Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Deciphering LKB1-associated immunotherapy resistance in lung adenocarcinoma (LUAD)
  P01CA257906 · NCI · EMORY UNIVERSITY · PI Haian Fu, Suresh S Ramalingam · fiscal years 2022 to 2026
  Named on NCT06495125
• Winship Cancer Institute Cancer Center Support Grant
  P30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · fiscal years 2009 to 2026
  Named on NCT06495125, NCT04262869